Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 11 Apr 2023 |